Skip to Main Content
Skip Nav Destination

Low Lymphoma Risk Post–CAR-T, Large Patient Review Shows

February 1, 2024

Abstract: A review of patients treated with CAR T-cell therapy at the University of Pennsylvania shows a minimal risk of secondary malignancies, supporting the safety consensus among experts and regulators. The 449-patient study found only one case of T-cell lymphoma that researchers deemed unrelated to CAR T-cell infusion, reinforcing the belief that the benefits of this therapy for most patients outweigh the potential risks.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal